Literature DB >> 2927053

Phospholipase A2--regulation and inhibition.

W Scheuer1.   

Abstract

Phospholipase A2 (PLA2) has been implicated in the pathogenesis of different diseases. Thus, the pharmacological intervention of PLA2 activity by specific inhibitors is of great therapeutical value in ameliorating pathological conditions. Despite a great number of published data regarding PLA2 inhibitors none has reached clinical application. Since enzyme activity can be greatly influenced by the experimental conditions of the test system used, a potent in vitro enzyme inhibitor does not indicate therapeutic effectiveness per se. In order to enhance the predictable value of an in vitro screening system for PLA2 inhibitors, a battery of test systems each measuring certain parameters should be applied. Considering the complex mechanism(s) of PLA2 it is extremely important to elucidate the exact inhibition mechanism of those compounds, which have passed these first filters. True inhibitors of PLA2 should then be evaluated in suitable ex vivo, in vivo models.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2927053     DOI: 10.1007/BF01711343

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  28 in total

1.  Source of the arachidonic acid released on stimulation of rat basophilic leukemia cells.

Authors:  M Garcia-Gil; R P Siraganian
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

2.  Structural and functional characterization of endonexin II, a calcium- and phospholipid-binding protein.

Authors:  D D Schlaepfer; T Mehlman; W H Burgess; H T Haigler
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Lipocortin inhibition of extracellular and intracellular phospholipases A2 is substrate concentration dependent.

Authors:  A J Aarsman; G Mynbeek; H van den Bosch; B Rothhut; B Prieur; C Comera; L Jordan; F Russo-Marie
Journal:  FEBS Lett       Date:  1987-07-13       Impact factor: 4.124

Review 4.  Role of secretory phospholipases A2 in the pathobiology of disease.

Authors:  P Vadas; W Pruzanski
Journal:  Lab Invest       Date:  1986-10       Impact factor: 5.662

Review 5.  Inositol trisphosphate and diacylglycerol: two interacting second messengers.

Authors:  M J Berridge
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

Review 6.  Platelet-activating factor as a mediator of allergic disease.

Authors:  P J Barnes; K F Chung; C P Page
Journal:  J Allergy Clin Immunol       Date:  1988-05       Impact factor: 10.793

7.  Studies on the arachidonic acid cascade--I. Inhibition of phospholipase A2 in vitro and in vivo by several novel series of inhibitor compounds.

Authors:  D P Wallach; V J Brown
Journal:  Biochem Pharmacol       Date:  1981-06-01       Impact factor: 5.858

8.  Recombinant tumor necrosis factor and interleukin-1 both stimulate human synovial cell arachidonic acid release and phospholipid metabolism.

Authors:  R W Godfrey; W J Johnson; S T Hoffstein
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

9.  Recombinant human lipocortin 1 inhibits thromboxane release from guinea-pig isolated perfused lung.

Authors:  G Cirino; R J Flower; J L Browning; L K Sinclair; R B Pepinsky
Journal:  Nature       Date:  1987 Jul 16-22       Impact factor: 49.962

10.  A major role for phospholipase A2 in antigen-induced arachidonic acid release in rat mast cells.

Authors:  K Yamada; Y Okano; K Miura; Y Nozawa
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

View more
  3 in total

Review 1.  Mechanisms of exercise-induced muscle fibre injury.

Authors:  R B Armstrong; G L Warren; J A Warren
Journal:  Sports Med       Date:  1991-09       Impact factor: 11.136

2.  Activation of Phospholipase A by Plant Defense Elicitors.

Authors:  S. Chandra; P. F. Heinstein; P. S. Low
Journal:  Plant Physiol       Date:  1996-03       Impact factor: 8.340

3.  Comparative protection against rat intestinal reperfusion injury by a new inhibitor of sPLA2, COX-1 and COX-2 selective inhibitors, and an LTC4 receptor antagonist.

Authors:  Thiruma V Arumugam; Naomi Arnold; Lavinia M Proctor; Michelle Newman; Robert C Reid; Karl A Hansford; David P Fairlie; Ian A Shiels; Stephen M Taylor
Journal:  Br J Pharmacol       Date:  2003-07-29       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.